Now PlayingEP. 1 Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis
From the Exam Room to the Formulary: Access Challenges in Adjunctive MDD TherapyByKen Cohen, MD,Samuel Wilkinson, MD,Greg Rhee, PhD, FACE,Michael E. Thase, MD,Nisha Bhide, PharmDSeptember 3rd 2026
Rethinking Standard of Care and the Promise of Functional CureByRaymond Chung, MD,Douglas Dieterich, MDSeptember 3rd 2026
Unmet Needs and Mechanisms: Understanding Adjunctive Antipsychotics in MDDByKen Cohen, MD,Samuel Wilkinson, MD,Greg Rhee, PhD, FACE,Michael E. Thase, MD,Nisha Bhide, PharmDSeptember 3rd 2026
The Next Frontier in Hepatitis B Functional and Virologic CureByRaymond Chung, MD,Douglas Dieterich, MDSeptember 3rd 2026
Treating Adolescents With Vitiligo: Adherence and Age MatterByRyan Haumschild, PharmD, MBA,David Rosmarin, MD,Seemal R. Desai, MD, FAAD,Jason Fehr, MA,Karan Lal, DO, MS, FAADSeptember 2nd 2026